MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
84.34
+0.58 (+0.69%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close83.76
Open84.30
Bid0.00 x 800
Ask0.00 x 900
Day's Range84.26 - 85.44
52 Week Range66.10 - 87.35
Volume5,967,463
Avg. Volume8,435,387
Market Cap215.942B
Beta (3Y Monthly)0.32
PE Ratio (TTM)23.65
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.20 (2.63%)
Ex-Dividend Date2019-09-13
1y Target EstN/A
Trade prices are not sourced from all markets
  • Make sure you 'can pay for it': What health care execs think about Medicare for All
    Yahoo Finance

    Make sure you 'can pay for it': What health care execs think about Medicare for All

    Given soaring health care costs and the upcoming general election in 2020, the debate over “Medicare for All” has become nearly possible to avoid.

  • A cancer patient's journey to the cutting edge of cancer therapy
    American City Business Journals

    A cancer patient's journey to the cutting edge of cancer therapy

    Jennifer Peterson, a tax partner at KPMG LLP, went through years of treatments, doctor's appointments and insurance calls before honing in on a successful therapy.

  • Seattle Genetics Up More Than 20% in 3 Months: Here's Why
    Zacks

    Seattle Genetics Up More Than 20% in 3 Months: Here's Why

    Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.

  • Merck CEO: Stepping down from Trump council was 'not a political issue'
    Yahoo Finance

    Merck CEO: Stepping down from Trump council was 'not a political issue'

    Kenneth Frazier, the CEO of pharmaceutical giant Merck, explains in a new interview why he decided to publicly resign from one of President Trump’s councils in the summer of 2017.

  • Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says
    Yahoo Finance

    Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says

    “Every person running for president has a plan to reduce pharmaceutical pricing,” Merck CEO Kenneth Frazier says. “Some of them I think are legitimate plans, some of them will hurt innovation, which we don’t want.”

  • Top Ranked Growth Stocks to Buy for October 10th
    Zacks

    Top Ranked Growth Stocks to Buy for October 10th

    Top Ranked Growth Stocks to Buy for October 10th

  • 4 Stocks From Highest Job-Creating Sectors in September
    Zacks

    4 Stocks From Highest Job-Creating Sectors in September

    Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.

  • Zacks

    J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

    Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.

  • Merck (MRK) Stock Moves -1.33%: What You Should Know
    Zacks

    Merck (MRK) Stock Moves -1.33%: What You Should Know

    Merck (MRK) closed the most recent trading day at $83.27, moving -1.33% from the previous trading session.

  • Merck CEO Ken Frazier set to open Yahoo Finance's All Markets Summit
    Yahoo Finance

    Merck CEO Ken Frazier set to open Yahoo Finance's All Markets Summit

    On Thursday, Kenneth Frazier, the CEO of pharmaceutical giant Merck (MRK), will kick off Yahoo Finance’s annual All Markets Summit in a keynote conversation

  • Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
    Zacks

    Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

    Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

  • The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson
    Zacks

    The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson

    The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson

  • Top Analyst Reports for General Dynamics, Merck & Progressive
    Zacks

    Top Analyst Reports for General Dynamics, Merck & Progressive

    Top Analyst Reports for General Dynamics, Merck & Progressive

  • Wall Street Loves These “Strong Buy” Dividend Stocks
    TipRanks

    Wall Street Loves These “Strong Buy” Dividend Stocks

    Stock go up, investor happy. Stock go down, investor... sad?Probably. In fact, we'd go so far as to say that's probably the ordinary reaction an investor has to a decline in the share price of a stock he or she owns -- but not all the time.You see, if the stock is question is a dividend stock, even a decline in stock price can be offset by the value of the dividend you're being paid to own it. What's more, because a stock's dividend yield is calculated by dividing the dividend amount by the stock price, the lower the stock price falls, the bigger the dividend yield becomes -- making the stock increasingly attractive to other dividend investors, and providing a backstop that can prevent the stock falling further!So how do you find great dividend stocks, popular on Wall Street, and attractive to dividend investors?Using the Stock Screener at TipRanks, you can screen for stocks rated "strong buy" by Wall Street analysts, and screen, too, for stocks paying better-than-average dividend yields. Combine these two attributes, and voila! You've got a great dividend stock candidate. Here are three of them:Sanofi (SNY) One of Europe's largest drugmakers, Paris-based Sanofi boasts a market capitalization north of $112 billion, more than $40 billion in annual sales, and net profits approaching $4 billion. Sanofi stock's a great cash generator as well, throwing off nearly $6.3 billion in cash over the last 12 months, enabling it to pay a market-beating dividend yield of 3.9%.Just recently, Morgan Stanley analyst Mark Purcell upgraded Sanofi shares to "overweight," calling the stock a "defensive" play in an uncertain market. According to Purcell, the stock is "largely de-risked" -- indeed, the analyst says Sanofi has the lowest risk growth outlook of any European Big Pharma stock, due to a lack of big drugs losing patent protection in the near future (the dreaded "patent cliff"), and a pipeline of new drugs in late-stage clinical trials that could soon come to market.Whereas the consensus on Wall Street is that Sanofi stock is worth $52 per share, Purcell thinks Sanofi could go all the way to ... $98 a share! (To watch Purcell's track record, click here)"We argue that new CEO Paul Hudson inherits significant optionality to unlock shareholder value alongside the recent CFO and CSO appointments. The management team can draw on their shared experience from the strategic transformations of AstraZeneca and Novartis, the new chapter of innovation at Roche and the cost discipline of Peugeot. The evolution of the GSK equity story, with which Sanofi has much in common, albeit with greater balance sheet flexibility and lower patent risk, offers a further yardstick for investors, we believe. We explore potential strategic options that could in theory help to close the 15% relative P/E multiple discount," Purcell said.Sanofi stock hasn't moved much over the past year, up less than 4%. Regardless, Wall Street loves Sanofi stock, rating it "strong buy" on average, and with a $52 price target implying 14.5% upside from today's prices. Factor in the dividend, and you're pushing 18.5% potential profit. (See Sanofi stock analysis on TipRanks)Merck (MRK) But you needn't travel all the way to Europe to find an attractive drug stock paying a big dividend. Right here at home, Kenilworth, New Jersey-based Merck & Co. pays its shareholders a very respectable 2.7% dividend yield. (The average stock on the S&P 500 is only paying 2%).Recently, Merck presented more positive data at ESMO supporting the use of Keytruda + chemo to treat neoadjuvant/adjuvant TNBC. These data, along with other data presented at ESMO, like BMY's (NC) Merck-227 data and the Lynparza ovarian data, support MRK's leadership in oncology.Morgan Stanley analyst David Risinger commented, "KN-522 demonstrated an impressive pathologic complete response (pCR), improving on results from its earlier exploratory KN-173 trial. On another key efficacy metric, event free survival (EFS), the trend to 18mo looks quite favorable but the trial’s discussant urged a measure of caution in over-interpreting the findings, saying data were too early still and need to mature. The reason for caution is that discontinuation rates were ~2x for Keytruda vs placebo (PBO), raising the specter that longer-term survival curves may look different than shown at the first, early look, if too many patients are stopping therapy prematurely. The discussant also reminded that certain immune-related adverse events would likely be permanent, implying a more definitive calculation of risk:benefit is warranted, but this is not yet possible from the preliminary data set."As a result, Risinger reiterated an Overweight rating on MRK stock with $90 price target, which implies nearly 7% upside from current levels. (Watch Risinger's track record, click here)Overall, the consensus targets on the Street see Merck shares rising as high as $100 per share over the next 12 months, 18% above current levels. (See Merck stock analysis on TipRanks)Verizon (VZ) Switching gears now from the somewhat esoteric world of biotech to a company we're all very familiar with, Verizon is our final stock to look at in today's column -- and for good reason.Investors have long viewed the telecom industry as a happy hunting ground for stocks paying robust dividends, and Verizon, which pays 4.2%, is no exception. In fact, Verizon has raised its dividend for 13 years in a row, with its latest dividend hiking coming just last month. At 4.2%, Verizon's dividend is now more than twice the market average.One analyst who likes Verizon more than most is Oppenheimer's Timothy Horan, who in August upgraded Verizon shares to "outperform" with a $70 price target implying better than 16% upside (and better than 20% with the dividend added in). Horan believes that Verizon will be an early beneficiary of the telecommunications industry's move to 5G wireless technology. And anticipating customer defections from T-Mobile and Sprint once those two companies merge, Horan predicts that Verizon will also benefit from customer "churn" at this wireless rival. (To watch Horan's track record, click here)Overall, Wall Street loves the stock, giving Verizon "strong buy" ratings by and large. Granted, with a consensus price target of "only" $65, most analysts don't see a huge amount of upside in the stock -- only about 9%. But if you add in the dividend yield, the potential profit on this one exceeds 13%, and maybe even more.Topping it all off, with a P/E of less than 16, Verizon's not just the biggest dividend payer on today's list of highly-rated dividend stocks -- it's also the cheapest. (See Verizon stock analysis on TipRanks)

  • The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
    Zacks

    The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

    The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

  • Novo Nordisk Focuses on Pipeline Development Amid Competition
    Zacks

    Novo Nordisk Focuses on Pipeline Development Amid Competition

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

  • GuruFocus.com

    US Indexes Close Higher Friday After Volatile Week

    Nasdaq gains 0.5% for the week Continue reading...

  • Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
    Zacks

    Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

    J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

  • Here is Hedge Funds’ 30th Most Popular Stock Pick
    Insider Monkey

    Here is Hedge Funds’ 30th Most Popular Stock Pick

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
    Zacks

    Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

    Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

  • Buying Merck? Here's the One Technical Level to Watch
    TheStreet.com

    Buying Merck? Here's the One Technical Level to Watch

    During Thursday night's Mad Money program Jim Cramer favored Merck & Co. Inc. noting that it is one of the few drug stocks that investors can bank on right now. In the daily bar chart of MRK, below, we can see that prices are trading between the weakening 50-day moving average line and the still bullish 200-day line. The On-Balance-Volume (OBV) line has also turned flat and suggests that buyers and sellers of MRK are generally in balance.

  • Benzinga

    Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

    Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization.

  • Merck CEO Kenneth Frazier: How innovation saves lives
    Yahoo Finance Video

    Merck CEO Kenneth Frazier: How innovation saves lives

    In a conversation with Yahoo Finance, Merck CEO Kenneth Frazier discusses an array of topics from drug price affordability to the anti-vaccination movement to his decision to step down from President Trump's American Manufacturing Council.

  • Yahoo Finance Video

    Yahoo Finance All Markets Summit: Generational Opportunities

    The Yahoo Finance All Markets Summit: Generational Opportunities event brings together leaders in business, government and a host of influencers who are shaping and defining new relationships in a time of profound generational change.